ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cariprazine

Also written as “Cariprazine”, “MP-214 3mg” and “MP-214 6mg”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Bipolar Disorder · Mania · Depression, led by 7 companies.

Drug pageCariprazine: every studyMany companies study it; this page follows only the 41 they lead. All 53 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jan 27, 201041 company-led studies, 4 open or runningNext primary completion: Dec 15, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie291 open or runningphase 3since Jan 27, 2010Nov 27, 2006Mar 2027phase 3 · NCT04777357
Tanabe Pharmaits history only60 open or runningphase 3since Jun 19, 2012Mar 15, 2009none ahead
Gedeon Richter Plc.its history only21 open or runningphase 3since Jan 24, 2019Jun 13, 2014Dec 15, 2026phase 3 · NCT03817502
Bostal Drug Deliveryits history only11 open or runningphase 3since Jul 15, 2026Jul 15, 2026Aug 2027phase 3 · NCT07722728
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Jul 1, 2026Jul 1, 2026none ahead
Mapi Pharmaits history only11 open or runningphase 2since Aug 28, 2025Aug 28, 2025Dec 31, 2026phase 2 · NCT07185815
Whanin Pharmaceuticalits history only10 open or runningphase 3since Nov 26, 2021Nov 26, 2021none ahead

Also a collaborator on its studies: Gedeon Richter.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Nov 27, 2006.

  1. Jul 15, 2011Phase 2 study in Bipolar DisorderNCT01396447 · 584 enrolled · United States, Bulgaria, Canada and more
  2. Aug 4, 2011Phase 3 study in SchizophreniaNCT01412060 · 765 enrolled · United States, India, Romania and more
  3. Nov 8, 2011Phase 2 study in Depressive Disorder, MajorNCT01469377 · 819 enrolled · United States, Estonia, Finland and more
  4. Oct 25, 2012Phase 3 study in Depressive Disorder, MajorNCT01715805 · 1,022 enrolled · United States, Puerto Rico
  5. Apr 22, 2013Phase 3 study in Depressive Disorder, MajorNCT01838876 · 442 enrolled · United States, Puerto Rico
  6. Jan 28, 20162 phase 3 studies in Bipolar DisorderNCT02670551, NCT02670538
  7. Jun 5, 2018Phase 3 study in ManiaNCT03573297 · 901 enrolled · United States, Bulgaria, Korea, Republic of and more
  8. Jul 10, 2018Phase 3 study in SchizophreniaNCT03593213 · 587 enrolled · United States, Bulgaria, Korea, Republic of and more
  9. Nov 8, 20182 phase 3 studies in Depressive Disorder, MajorNCT03738215, NCT03739203
  10. Mar 19, 2020Phase 1 study in Autism Spectrum DisorderNCT04382885 · 24 enrolled · United States
  11. Feb 26, 2021Phase 3 study in DepressionNCT04777357 · 338 planned · United States, Puerto Rico, Russia
  12. Jul 7, 2021Phase 2 study in Generalized Anxiety DisorderNCT04965272 · United States
  13. May 6, 2022Phase 3 study in SchizophreniaNCT05368558 · 34 enrolled · Japan, Taiwan
  14. Jun 28, 2022Phase 3 study in Autism Spectrum DisorderNCT05439616 · 161 enrolled · United States, Puerto Rico

Ahead

  1. Mar 2027Primary completion: phase 3 study in DepressionNCT04777357

TargetBeta

DRD2 →DRD3 →read by rule
“Dopamine D3 receptor modulator; Dopamine D2 receptor modulator”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464
PramipexoleruleBoehringer Ingelheimphase 444
ABBV-932AbbViephase 210

Studies

All 29 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05439616Autism Spectrum Disorder · United States, Puerto Rico3CompletedOct 4, 2024161
NCT05368558Schizophrenia · Japan, Taiwan3TerminatedSep 20, 202434
NCT04965272Generalized Anxiety Disorder · United States2WithdrawnAug 24, 20210
NCT04777357Depression · United States, Puerto Rico, Russia3RecruitingMar 2027338
NCT04382885Autism Spectrum Disorder · United States1CompletedDec 10, 202124
NCT03739203Depressive Disorder, Major · United States, Canada, Czechia and more3CompletedSep 6, 2021752
NCT03738215Depressive Disorder, Major · United States, Bulgaria, Estonia and more3CompletedSep 30, 2021759
NCT03593213Schizophrenia · United States, Bulgaria, Korea, Republic of and more3TerminatedFeb 11, 2021587
NCT03573297Mania · United States, Bulgaria, Korea, Republic of and more3CompletedSep 5, 2022901
NCT02670551Bipolar Disorder · United States, Bulgaria, Estonia and more3CompletedJul 19, 2017488
NCT02670538Bipolar Disorder · United States, Bulgaria, Croatia and more3CompletedJan 18, 2018493
NCT01838876Depressive Disorder, Major · United States, Puerto Rico3CompletedJul 27, 2015442
NCT01715805Depressive Disorder, Major · United States, Puerto Rico3CompletedJun 24, 20161,022
NCT01469377Depressive Disorder, Major · United States, Estonia, Finland and more2CompletedDec 12, 2013819
NCT01412060Schizophrenia · United States, India, Romania and more3CompletedSep 3, 2014765
NCT01396447Bipolar Disorder · United States, Bulgaria, Canada and more2CompletedJan 10, 2014584
NCT01376076Schizophrenia · United States1CompletedFeb 2012129
NCT01104779Schizophrenia · United States, Colombia, India and more3CompletedDec 15, 2011446
NCT01104792Schizophrenia · United States, Colombia, India and more3CompletedJan 31, 2013752
NCT01104766Schizophrenia · United States, Romania, Russian Federation and more3CompletedDec 20, 2011617
NCT01059539Mania · United States, Hungary, Poland and more3CompletedFeb 29, 2012403
NCT01058668Mania · United States, Croatia, Romania and more3CompletedDec 2011497
NCT01058096Bipolar Disorder · United States, India3CompletedJul 2011323
NCT00854100Depressive Disorder, Major · United States2CompletedDec 6, 2010231
NCT00852202Bipolar Disorder · United States2CompletedJun 15, 2010234
NCT00839852Schizophrenia · United States, India, Malaysia and more2CompletedAug 31, 201097
NCT00694707Schizophrenia · United States, India, Malaysia and more2CompletedAug 31, 2009732
NCT00488618Bipolar Disorder · United States2CompletedJul 2008238
NCT00404573Schizophrenia · United States2CompletedAug 2007375

How it is read

Names in the registry

  • “Cariprazine”, 25 entries
  • “MP-214 3mg”, 3 entries
  • “MP-214 6mg”, 3 entries
  • “MP-214 9mg”, 3 entries
  • “MP-214”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.